The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active Crohn’s disease, drugmaker Eli Lilly announced; the first-in-class interleukin-23 antagonist was previously approved for ulcerative colitis. In Crohn’s disease patients, adherence to a Mediterranean diet was associated with better clinical outcomes and decreases in markers of inflammation, […]

PR Newswire

United States

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults.

Medical Xpress

FDA approves Omvoh for moderately to severely active Crohn's disease

INDIANAPOLIS (WISH) — Indianapolis-based Lilly announced Thursday that the U.S. Food and Drug Administration has approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for two types of inflammatory bowel disease (IBD), following its October 2023 approval as a first-in-class treatment for moderately to severely active ulcerative colitis (UC) in adults. Omvoh works to reduce i…

All Sides

Media Bias/Fact Check

WISH-TV

Indianapolis

Marion County

Indiana

FDA approves Lilly's Omvoh for Crohn's disease

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for...

Cision

THURSDAY, Jan. 16, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults, according

HealthDay

FDA Approves Omvoh for Moderately to Severely Active Crohn Disease

THURSDAY, Jan. 16, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults, according to a press release from Eli Lilly and Company. Omvoh targets interleukin-23p19, which contributes to intestinal inflammation. Omvoh is the first biological treatment for Crohn

FOX 28 Spokane

Ad Fontes Media

MedPage Today

New York

Omvoh Approved for Crohn’s; Fitbit Predicts IBD Flares; H. Pylori and Gastric Cancer

In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year Among those who achieved clinical remission and endoscopic response at one year, nearly 90% of patients maintained clinical remission with two years of continuous Omvoh treatment in open-label extension INDIANAPOLIS, IN, USA I January 15, 2025 I Eli Lilly and Company (NYSE: LLY) announced…

pipelinereview

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease - Pipelinereview

The FDA approved Eli Lilly’s Omvoh in Crohn’s disease, the company announced Wednesday, handing the drug its second indication after giving it a green light for ulcerative colitis in late 2023.
While Lilly is largely ...

Endpoints News

Eli Lilly's Omvoh earns FDA approval for Crohn's disease

This is mirikizumab’s second FDA-approved indication in inflammatory bowel disease.

Pharmacy Times

FDA Approves Mirikizumab-Mrkz to Treat Adult Patients With Crohn Disease

Eli Lilly picks up a second FDA approval for IL-23 inhibitor Omvoh in Crohn's disease, but will it kickstart sales growth.

Omvoh Approved for Crohn’s; Fitbit Predicts IBD Flares; H. Pylori and Gastric Cancer

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics